Alternative MRI contrast agent may reduce gadolinium brain deposits in multiple sclerosis patients

Written by Martha Powell

Researchers from Charité–Universitätsmedizin Berlin (Germany) and the Max Delbrück Center for Molecular Medicine (Berlin, Germany) have examined the use of linear and macrocyclic MRI contrast agents in multiple sclerosis (MS) patients. The team demonstrated that deposits caused by repeated use of linear contrast agents could be reduced by utilizing alternative macrocyclic agents and have suggested that this discovery could improve future clinical practice. The study, published recently in the Multiple Sclerosis Journal, examined contrast agents based on the rare earth element gadolinium. It has been reported in other patient groups that use of gadolinium-based MRI agents can lead to permanent...

To view this content, please register now for access

It's completely free